Evaluation of human T-cell leukemia virus in vitro diagnostics using plasma specimens collected in Japan

In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Th...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 23; no. 1; pp. 418 - 8
Main Authors Kusagawa, Shigeru, Kawana-Tachikawa, Ai, Matsubayashi, Keiji, Sobata, Rieko, Hamaguchi, Isao
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 20.06.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
AbstractList Abstract Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Methods The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. Results The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Conclusions Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. Methods The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. Results The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Conclusions Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score. Keywords: HTLV IVDs, New generation products, Sensitivity, Specificity
In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan. The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center. The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%). Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.BACKGROUNDIn vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.METHODSThe performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).RESULTSThe diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.CONCLUSIONSSix sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
ArticleNumber 418
Audience Academic
Author Hamaguchi, Isao
Matsubayashi, Keiji
Kusagawa, Shigeru
Kawana-Tachikawa, Ai
Sobata, Rieko
Author_xml – sequence: 1
  givenname: Shigeru
  surname: Kusagawa
  fullname: Kusagawa, Shigeru
– sequence: 2
  givenname: Ai
  surname: Kawana-Tachikawa
  fullname: Kawana-Tachikawa, Ai
– sequence: 3
  givenname: Keiji
  surname: Matsubayashi
  fullname: Matsubayashi, Keiji
– sequence: 4
  givenname: Rieko
  surname: Sobata
  fullname: Sobata, Rieko
– sequence: 5
  givenname: Isao
  surname: Hamaguchi
  fullname: Hamaguchi, Isao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37340346$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhgep2A_9A15IwJt6MTXfyV5JKbWuFAq6eBvOZpLZ1Jlkncxs9d83262lC15ILhKS5zwcTt7j6iCm6KrqLcFnhGj5MROq1azGlNVYc0zruxfVEeGK1JQxfvDsfFgd53yLMVGazl5Vh0wxjhmXR9XqcgPdBGNIESWPVlMPES1q67oOdW766foAaBOGKaMQy2EcEmoCtDHlMdiMphxii9Yd5B5QXjsbehczsqnrnB1ds636CmuIr6uXHrrs3jzuJ9Xi8-Xi4kt9fXM1vzi_rq0QYqy10Eo1zmo-c1546iSRjfdScezFcimptIop6QFrhzktT4o1TBOsABQIdlLNd9omwa1ZD6GH4Y9JEMzDRRpaA0PpvHNGCUUJpgLEjHOxrS8qi8HRGXDQpLg-7Vzradm7xro4DtDtSfdfYliZNm1MsWpGNCuG00fDkH5NLo-mD3k7W4guTdlQXUDJFMYFfb9DWyi9hehTUdotbs6VYFphKXWhzv5BldWUj7IlHj6U-72CD3sFhRnd77GFKWcz__7t_9mbH_vsu-ezeRrK32QVgO4AO6ScB-efEILNNr5mF19T4mse4mvu2D1Kc-BV
Cites_doi 10.1186/s12977-020-00534-0
10.1128/JCM.00169-17
10.1128/CVI.00053-16
10.1016/s0140-6736(86)91298-5
10.1128/JCM.01384-19
10.7754/Clin.Lab.2016.160501
10.1128/JCM.01628-15
10.1002/jcla.22909
10.1097/COH.0b013e3283506613
10.1016/s1473-3099(16)30252-3
10.3389/fmicb.2012.00388
10.1016/j.antiviral.2016.10.015
10.1016/j.diagmicrobio.2009.12.021
10.3389/fmicb.2020.01151
10.1002/jmv.21083
10.1073/pnas.79.6.2031
10.1128/JCM.00659-17
10.1002/jmv.21867
10.1186/s12879-020-05282-2
10.1007/s12185-011-0934-4
10.1128/JCM.37.5.1324-1328.1999
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
7X8
5PM
DOA
DOI 10.1186/s12879-023-08402-w
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2334
EndPage 8
ExternalDocumentID oai_doaj_org_article_75721025a594457aa773dc0ae29a4a81
PMC10283183
A753870668
37340346
10_1186_s12879_023_08402_w
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7X8
PPXIY
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c555t-85877dec849ef5f2e616dff6740f5bb626c7376fa08e042dff73d38107aa7a53
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:15:28 EDT 2025
Thu Aug 21 18:36:52 EDT 2025
Fri Jul 11 05:45:06 EDT 2025
Tue Jun 17 20:48:33 EDT 2025
Tue Jun 10 20:13:59 EDT 2025
Fri Jun 27 05:43:56 EDT 2025
Fri Jun 27 05:53:52 EDT 2025
Thu Jan 02 22:52:21 EST 2025
Tue Jul 01 03:10:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Sensitivity
Specificity
New generation products
HTLV IVDs
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c555t-85877dec849ef5f2e616dff6740f5bb626c7376fa08e042dff73d38107aa7a53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-023-08402-w
PMID 37340346
PQID 2828363700
PQPubID 23479
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_75721025a594457aa773dc0ae29a4a81
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10283183
proquest_miscellaneous_2828363700
gale_infotracmisc_A753870668
gale_infotracacademiconefile_A753870668
gale_incontextgauss_ISR_A753870668
gale_incontextgauss_IOV_A753870668
pubmed_primary_37340346
crossref_primary_10_1186_s12879_023_08402_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-20
PublicationDateYYYYMMDD 2023-06-20
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-20
  day: 20
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References M Kuramitsu (8402_CR9) 2017; 55
M Kuramitsu (8402_CR8) 2015; 53
TS Alexander (8402_CR11) 2016; 23
K Umeki (8402_CR20) 2017; 63
K Okuma (8402_CR7) 2020; 17
S Laperche (8402_CR16) 2017; 55
H Ji (8402_CR18) 2020; 11
M Satake (8402_CR5) 2012; 84
J Zhao (8402_CR17) 2020; 20
SM Owen (8402_CR10) 2012; 7
K Malm (8402_CR13) 2010; 82
EC Sabino (8402_CR19) 1999; 37
L Willems (8402_CR4) 2017; 137
A Gessain (8402_CR3) 2012; 3
HP Kapprell (8402_CR12) 2010; 67
M Yoshida (8402_CR1) 1982; 79
8402_CR15
M Satake (8402_CR6) 2016; 16
KR Campos (8402_CR21) 2019; 58
M Osame (8402_CR2) 1986; 1
X Qiu (8402_CR14) 2008; 80
References_xml – volume: 17
  start-page: 26
  issue: 1
  year: 2020
  ident: 8402_CR7
  publication-title: Retrovirology
  doi: 10.1186/s12977-020-00534-0
– volume: 55
  start-page: 2180
  issue: 7
  year: 2017
  ident: 8402_CR16
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00169-17
– volume: 23
  start-page: 249
  issue: 4
  year: 2016
  ident: 8402_CR11
  publication-title: Clin Vaccine Immunol
  doi: 10.1128/CVI.00053-16
– volume: 1
  start-page: 1031
  issue: 8488
  year: 1986
  ident: 8402_CR2
  publication-title: Lancet
  doi: 10.1016/s0140-6736(86)91298-5
– volume: 58
  start-page: e01384
  issue: 1
  year: 2019
  ident: 8402_CR21
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01384-19
– volume: 63
  start-page: 227
  issue: 2
  year: 2017
  ident: 8402_CR20
  publication-title: Clin Lab
  doi: 10.7754/Clin.Lab.2016.160501
– volume: 53
  start-page: 3485
  issue: 11
  year: 2015
  ident: 8402_CR8
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01628-15
– ident: 8402_CR15
  doi: 10.1002/jcla.22909
– volume: 7
  start-page: 125
  issue: 2
  year: 2012
  ident: 8402_CR10
  publication-title: Curr Opin HIV AIDS
  doi: 10.1097/COH.0b013e3283506613
– volume: 16
  start-page: 1246
  year: 2016
  ident: 8402_CR6
  publication-title: Lancet Infect Dis
  doi: 10.1016/s1473-3099(16)30252-3
– volume: 3
  start-page: 388
  year: 2012
  ident: 8402_CR3
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2012.00388
– volume: 137
  start-page: 41
  year: 2017
  ident: 8402_CR4
  publication-title: Antiviral Res
  doi: 10.1016/j.antiviral.2016.10.015
– volume: 67
  start-page: 61
  issue: 1
  year: 2010
  ident: 8402_CR12
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2009.12.021
– volume: 11
  start-page: 1151
  year: 2020
  ident: 8402_CR18
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2020.01151
– volume: 80
  start-page: 484
  issue: 3
  year: 2008
  ident: 8402_CR14
  publication-title: J Med Virol
  doi: 10.1002/jmv.21083
– volume: 79
  start-page: 2031
  issue: 6
  year: 1982
  ident: 8402_CR1
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.79.6.2031
– volume: 55
  start-page: 2838
  issue: 9
  year: 2017
  ident: 8402_CR9
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00659-17
– volume: 82
  start-page: 1606
  issue: 9
  year: 2010
  ident: 8402_CR13
  publication-title: J Med Virol
  doi: 10.1002/jmv.21867
– volume: 20
  start-page: 581
  issue: 1
  year: 2020
  ident: 8402_CR17
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-020-05282-2
– volume: 84
  start-page: 327
  year: 2012
  ident: 8402_CR5
  publication-title: J Med Virol
  doi: 10.1007/s12185-011-0934-4
– volume: 37
  start-page: 1324
  issue: 5
  year: 1999
  ident: 8402_CR19
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.37.5.1324-1328.1999
SSID ssj0017829
Score 2.3694618
Snippet In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in...
Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation...
Abstract Background In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 418
SubjectTerms Algorithms
Analysis
Blood banks
Breast feeding
Care and treatment
Diagnosis
Diagnostic reagents
Health aspects
HTLV IVDs
HTLV-I Infections - diagnosis
Human T-lymphotropic virus 1
Human T-lymphotropic virus 2
Humans
Japan
Leukemia
Leukemia, T-Cell
Maternal-fetal exchange
New generation products
Sensitivity
Specificity
T cells
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k3agtwKiQOKmo2fORbUqlQqSLCg3izHsdsVNKk2G_r3mXGyq7UQ4sItiidRPDOeRzzzmZA3Iqg6COdy8JUu57Ks8rridT5zzAutnZ9FnO2LT_LsGz-_FJdbR31hTdgIDzwy7kgJhVmJsKLiXChrlWKNK6wvK8ttbLouweetk6lp_wD8XrVukdHyqAcrrKoc_BPimIINuEvcUETr_9MmbzmltGByywOdPiIPp9CRHo-f_Jjc8-0Tcv9i2hx_Sq5PNsjdtAs0nr5H5zn-mqc__fDD3yws_bVYDj1dtHCxWna0GSvtEKuZYgn8Fb2FcPrGUuzAROD_nqKmgFX0DT51Dr61fUbmpyfzD2f5dJBC7oQQq1wLrVTjneaVDyKUXs5kE4JUvAiiriGncQoMTbCF9rCIYQh4jNBfyG4r2HOy03atf0looUPhmtDwGoHiuLQQHkrG4UWqbmaVzci7NVvN7QiXYWKaoaUZhWBACCYKwdxl5D1yfkOJUNfxBiiAmRTA_EsBMnKIcjMIZtFitcyVHfrefPz83RxDLob7uFL_jejrl4To7UQUOhCzs1OHAkwdQbISyv2EEpakS4YP1jpkcAjr2FrfDb3BBJdJpooiIy9GndrMninGC8ZlRnSibQl70pF2cR0RwWOUCMZ5938wdI88KONKkWBC98nOajn4VxB5rerXcZH9BocnKWc
  priority: 102
  providerName: Directory of Open Access Journals
Title Evaluation of human T-cell leukemia virus in vitro diagnostics using plasma specimens collected in Japan
URI https://www.ncbi.nlm.nih.gov/pubmed/37340346
https://www.proquest.com/docview/2828363700
https://pubmed.ncbi.nlm.nih.gov/PMC10283183
https://doaj.org/article/75721025a594457aa773dc0ae29a4a81
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2kaa9IO4rjMogJB5QIGl8ywNC69RpTOpApUMTL5bj2F3Flo6mZfDvOcdNSyPGCy9RVB9Xic89Pv4OIS-5l7nn1kbgK23ERCeL8ozlUWJTx5WyLgk42_1TcXzGTs75-QZZtjuqF7C6NbXDflJn08s3P7__eg8K_y4ovBJvK7CxMovA-yBKKWj4zSbZBs8ksaNBn_3ZVQBvmC0Pztw6b5fspDJlcYrx8JqfCnD-fxvtNa_VrKhcc1FHd8mdOrakBwthuEc2XHmf7PTr3fMH5KK3gvamE09Dez46jPDbPb1082_uamzoj_F0XtFxCTez6YQWi1I8BHOmWCM_otcQb18Zikc0sTNARVGUwGy6AmedgPMtH5LhUW94eBzVnRYiyzmfRYorKQtnFcuc577jRCIK74Vksed5DkmPlWCJvImVAy2HIZkWiA0mjZGGp4_IVjkp3R6hsfKxLXzBckSSY8JA_ChSBn8k8yLJTIu8Xi6rvl7gaeiQhyihF_zQwA8d-KFvWqSLK7-iRCzs8MNkOtK1amnJJeat3PCMMY5PBA9nY-M6mWFGJS3yAvmmEe2ixHKakZlXlf7w8Ys-gGQNN3qF-hfR50GD6FVN5CfAZmvqIwzw6oii1aDcb1CCztrG8POlDGkcwkK30k3mlcYMOBWpjOMWebyQqdXbL0WzRVRD2hrL0xwpxxcBMjyEkWC9n_z_1KdktxNURYBl3Sdbs-ncPYOAbJa3yaY8l3BVh0mbbHd7p58G7fBxox30D66D7tffXoQ4Pw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+human+T-cell+leukemia+virus+in+vitro+diagnostics+using+plasma+specimens+collected+in+Japan&rft.jtitle=BMC+infectious+diseases&rft.au=Kusagawa%2C+Shigeru&rft.au=Kawana-Tachikawa%2C+Ai&rft.au=Matsubayashi%2C+Keiji&rft.au=Sobata%2C+Rieko&rft.date=2023-06-20&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=23&rft_id=info:doi/10.1186%2Fs12879-023-08402-w&rft_id=info%3Apmid%2F37340346&rft.externalDocID=PMC10283183
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon